comparemela.com

Latest Breaking News On - Snmmi - Page 1 : comparemela.com

Clovis Oncology Announces Second Quarter 2022 Operating Results and Provides Update on Clinical Development Programs

First presentation of initial LuMIERE Phase 1 clinical data for FAP-2286 targeted radiotherapy candidate at SNMMI demonstrated a manageable safety profile with preliminary evidence of. | August 8, 2022

United statesComunidad autonoma de catalunaPatrickj mahaffyClovis oncology incEuropean network of gynaecological oncological trialDrug administrationGynecologic oncology groupEuropean association of nuclear medicineExchange commissionOncologic drugs advisory committeeCongress onEuropean medicines agencyNorthstar medical radioisotopesClovis oncologySixth street partnersNuclear medicine

Positive New Data from Phase 1/2 Trial of AT-01 (Iodine

AT-01 is the first pan-amyloid imaging agent capable of detecting diverse types of systemic amyloidosisAT-01 visualizes and quantifies organ-specific.

British columbiaSan franciscoUnited statesEmily martinLuke heagleAttralus incUniversity of tennessee research foundationSociety of nuclear medicine molecular imagingUniversity of tennessee graduate school medicineCancer theranostics programTennessee graduate schoolNuclear medicineMolecular imagingAnnual meetingImaging resultsOral presentation

Attralus to Present New AT-01 Data at 2022 Society of

Final Phase 1/2 Study Results for AT-01 (Evuzamitide), Attralus's Novel Pan-Amyloid Imaging Agent for the Detection of Systemic Amyloidosis Repeat PET/CT.

British columbiaSan franciscoUnited statesEmily martinLuke heagleGregory bellAttralus incUniversity of tennessee research foundationSociety of nuclear medicine molecular imagingUniversity of tennessee graduate school medicineCancer theranostics programFinal phaseNovel pan amyloid imaging agentSystemic amyloidosisIdentifies organ specificTennessee graduate school

Attralus to Present New AT-01 Data at 2022 Society of

Final Phase 1/2 Study Results for AT-01 (Evuzamitide), Attralus's Novel Pan-Amyloid Imaging Agent for the Detection of Systemic Amyloidosis Repeat PET/CT.

British columbiaSan franciscoUnited statesEmily martinLuke heagleGregory bellAttralus incUniversity of tennessee research foundationSociety of nuclear medicine molecular imagingUniversity of tennessee graduate school medicineCancer theranostics programFinal phaseNovel pan amyloid imaging agentSystemic amyloidosisIdentifies organ specificTennessee graduate school

Brain PET algorithm shows promise in diagnosing Parkinson s disease

Researchers have developed an artificial intelligence (AI) deep-learning model that may help clinicians diagnose parkinsonian diseases.

Ping wuJournal of nuclear medicineParkinsonism differential diagnosis networkFudan universitySociety for nuclear medicineNuclear medicineMolecular imagingArtificial intelligenceArkinson 39s diseasePet imaging

vimarsana © 2020. All Rights Reserved.